ClinicalTrials.gg
RecruitingNCT05459402Updated Feb 3, 2026

Divided or Single Exposure (DOSE) Study

A Phase 2/3 interventional study of Methadone (100% dose) and Methadone (50% dose) in Opioid Use Disorder, Chronic Pain and Methadone, sponsored by University of Maryland, Baltimore. Recruiting at 1 site in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-02-03.

Sponsored by University of Maryland, Baltimore · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 19 studies testing methadone in Opioid-Related Disorders — 4 open to participants now, 4 under way, 1 of them phase 3. Methadone · Opioid-Related Disorders.

Planned enrollment
8th of 19
150 · median 68
Started
2023
with 1 other
Phase 2/3
2 of 19
1 open now
Registered
16th of 19
by date

Among the 19 studies testing methadone in Opioid-Related Disorders, this one is the 8th largest by planned enrollment, is one of 2 that started in 2023, is one of 2 in phase 2/3, and was the 16th registered.

Opioid-Related Disorders

1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.

Browse Opioid-Related Disorders studies →

Open to participants now

4 of the 19 studies testing methadone in Opioid-Related Disorders are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About methadone

Methadone: first FDA approval 1947 (DOLOPHINE HYDROCHLORIDE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing methadone in Opioid-Related Disorders, or all of them as a file.
02

Study summary

This study will evaluate whether once versus twice daily dosing of methadone will be an effective method for managing comorbid pain and opioid use disorder.

Read the detailed description

This study follows a successfully completed project (NCT03254043) to now pursue the investigators overarching goal of optimizing methadone dosing as a method for managing comorbid chronic pain and opioid use disorder (OUD) among persons receiving methadone for the treatment of OUD. Up to 62% of persons maintained on methadone for OUD experience clinically significant pain, versus 31% in the general population. Pain in methadone-maintained persons (MMP) is associated with poor OUD treatment outcomes and severe distress. No effective treatment for comorbid pain and OUD currently exists; though preclinical and human data suggest divided methadone dosing may be a more optimal strategy for managing pain than once daily dosing, this has never been empirically examined. This study will evaluate an intervention for comorbid chronic pain among MMP using a Phase II double-blind, randomized, placebo-controlled comparison of treatment as usual (TAU) versus split daily methadone dosing for 12-weeks. Methadone will be remotely managed via an electronic pillbox. Outcomes will include weekly assessments of pain and OUD outcomes, ecological momentary assessment of pain before and after dosing, and point-prevalence measures of laboratory-induced pain to explore mechanism of effects. If effective, this approach could transform the care of MMP with pain because it would be feasible to implement within the operational structure of a methadone clinic and would impose low provider burden. Results could provide a high magnitude treatment for the substantial number of MMP who experience daily pain with no reliable form of treatment.

03

Conditions studied

  • Opioid Use Disorder
  • Chronic Pain
  • Methadone
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 years of age or older
  • Currently receiving methadone for treatment of OUD for >90 days and have been consuming the same dose for >30 days
  • Have previously received a take-home dose of methadone as part of routine care
  • Willing to comply with study schedule
  • Report pain (specific definition blinded)
  • Have a cellular phone or be willing to carry phone provided by the study during one phase of the study

Exclusion criteria

Exclusion Criteria:

  • Pregnant
  • Presence of acute medical problem that requires immediate and intense medical management
  • Presence of a serious and unstable mental illness that interferes with provision of voluntary and/or adherence to study visits
  • Plans to leave methadone treatment during the study period
  • Maintained on a dose of methadone that would prevent effective splitting of doses
  • Currently receiving split doses of methadone
  • Currently receiving treatment for pain for which the split-dosing of methadone is judged by medical staff to be or otherwise interfere with study conduct or integrity
  • Does not meet criteria for mild-severe disability (definition blinded)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Active comparator
    Treatment as Usual (TAU)

    Participants in treatment as usual group will receive 100% active methadone in AM + placebo in PM.

    Drug: Methadone (100% dose)

  • Experimental
    Split-dosing

    Participants in split dosing group will receive 50% active methadone + placebo twice daily.

    Drug: Methadone (50% dose)

Interventions

06

What researchers measure

Primary outcomes

  1. Change in worst pain rating- past 24 hour as assessed by the Brief Pain Inventory scale

    Using the Brief Pain Inventory rating of "Worst Pain" in the past 24 hours, rated on a scale of 1-10, collected once weekly during weeks 1 through 12 of the intervention.

    Time frame: Week 1 up to week 12

Secondary outcomes

  1. Change in Pain Tolerance Latency

    Time in seconds (0-300) to removal of hand from cold pressor measure of laboratory-induced pain, collected point-prevalence during weeks 1, 6, and 12 of the intervention.

    Time frame: Weeks 1, 6, and 12

  2. Change in Pain Interference- past 7 days as assessed by Pain-related Disability Scale Total Score

    Past 7 day Pain-related Disability Scale Total Score (range 0-70), collected once weekly during weeks 1 through 12 of the intervention.

    Time frame: Week 1 up to 12

  3. Change in Opioid Withdrawal Severity- past 24 hours as assessed by the Subjective Opioid Withdrawal Scale

    Past 24 hour total score (range 0-64) for the Subjective Opioid Withdrawal Scale (SOWS), collected once weekly during weeks 1 through 12 of the intervention.

    Time frame: Week 1 up to 12

07

Study locations

1 of 1 sites recruiting
  • Addiction Treatment Services (ATS)
    Baltimore, Maryland 21224, United States
    Recruiting
    • Denis Antoine, MD · Contact
08

References and documents

Publications

  • McKendrick G, Davis W, Sklar M, Brown N, Pattillo E, Finan PH, Antoine D, Walters V, Dunn KE. The IMPOWR Network Divided or Single Exposure Study (DOSE) Protocol: A Randomized Controlled Comparison of Once Versus Split Dosing of Methadone for the Treatment of Comorbid Chronic Pain and Opioid Use Disorder. Subst Use Addctn J. 2025 Jan;46(1):197-200. doi: 10.1177/29767342241239167. Epub 2024 Mar 25. PubMed 38528704 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Jun 2027, 51 months after the start.

Of 18 phase 2/3 interventional studies under Opioid-Related Disorders, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 85. This study's planned 51 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2022
First posted
Jul 15, 2022
StartActual
Feb 21, 2023
Primary completionEst.
Jun 1, 2027
CompletionEst.
Jun 1, 2028
Last update
Feb 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05459402
Responsible party
Sponsor
First posted
Jul 15, 2022
Start date
Feb 21, 2023
Primary completion
Jun 1, 2027 (estimated)
Completion
Jun 1, 2028 (estimated)
Last update
Feb 3, 2026

Study contacts

Kelly E Dunn, PhD, M.B.A.
Contact
kelly.dunn@som.umaryland.edu
802-922-1682
Kelly E Dunn, PhD, M.B.A.
principal investigator · University of Maryland
Denis Antoine, MD
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methadone

Start the discussion